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Abstract
Pathologic processes associated with the effect of ischemia on the pancreas are not yet fully investigated and searching for ways
of reduction of the damaging effect of ischemia for providing full organ regeneration are of certain interest. Protective properties
of xymedone with regard to pathologic processes in pancreas were studied on a model of total ischemia created by ligation of the
coeliac and cranial mesenteric artery for 0 to 90 min. Pathologic structural changes in the pancreas in case of ischemia lasting up
to 30min are minor and therefore fully reversible. On the contrary, ischemia duration of more than 60min in the group of animals
not injected with xymedone can be seen as critical. We conclude that prior intraperitoneal injection of xymedone in the dose of
3.3 mg/kg helps to delay the development of pathologic processes in pancreatic parenchyma by approximately 30 min.
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1 Introduction
The issue of ischemic damages to various organs and tissues
remains one of the most pressing and understudied in the
medicine. In spite of seemingly well-studied consequences
of hypoxia for many organs and tissues, in general, the mech-
anisms of ischemic damages to various cells and the possibil-
ity of their future regeneration remain underinvestigated. The
effects of ischemia on the heart [1], brain [2], and pancreas [3]
are being studied by many scientists and, increasingly fre-
quently, using new study methods.
In our opinion, issues associated with the effect of ischemia
on the pancreas and the maximal reduction of the damaging
effect of ischemia for providing full organ regeneration as well
as delaying the irreversible changes as much as possible are of
certain interest. The approach involving pharmacological cor-
rection of ischemic lesions can be promising in this respect.
Molecular and clinical signs of organ ischemia can contrib-
ute to multiple organ dysfunction syndrome as a result of
oxidation processes and inflammatory response after reperfu-
sion [4]. The resulting active forms of oxygen are very
unstable. They can cause cell damage, primarily due to lipid
peroxidation in cellular membranes and mitochondria, as well
as DNA degradation [5]. It has been proven that overproduc-
tion of oxygen free radicals in organs causes suppression and
decreased ability to absorb own endogenous antioxidants
through the lipid peroxidation component of the mitochondri-
al and cellular membrane, which leads to cell death [6].
At the present time, to reduce the damaging effect of free
radicals, a wide range of drugs is being used such as antioxi-
dants, various enzyme blockers, and drugs improving microcir-
culation. Recently, protective properties of a drug from the group
of pyridine bases have been studied on various models. Among
them, xymedone (1,2-dihydro-4,6-dimethyl-N-(β-oxyethyl)-
pyrimidone-2) synthesised in 1966 by A.E. Arbuzov Institute
of Organic and Physical Chemistry of Kazan Scientific Centre
of the Russian Academy of Sciences and by the Kazan State
Medical University is of principal interest.
The preparation is a white or touched with pink crystalline
powder, without odour, bitterish, with the melting temperature of
139–143 °C, freely soluble in water, spirit, and normal saline.
According to the literature, xymedone has antioxidant [7],
apoptosis-regulating [8], burn-treating [9, 10], and antimutagenic
[11] effects, as well as immunomodulatory effect [12]. There are
data confirming the positive effect of xymedone on the treatment
of ischemic ulcers [13], systemic sclerosis [14], atopic asthma
[15], peritonitis [16], and sinusites [17]. In our previous study, we
showed that intraperitoneal introduction of xymedone in the
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